Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany

BACKGROUND: Multiple sclerosis (MS), a progressive neurodegenerative disease, greatly impacts the quality of life and economic status of people affected by this disease. In Germany, the total annual cost of MS is estimated at €40,000 per person with MS. Natalizumab has shown to slow MS disease progr...

Full description

Saved in:
Bibliographic Details
Published in:Clinicoecon Outcomes Res
Main Authors: Watson, Crystal, Prosser, Christine, Braun, Sebastian, Landsman-Blumberg, Pamela B, Gleissner, Erika, Naoshy, Sarah
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2017
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5293187/
https://ncbi.nlm.nih.gov/pubmed/28203098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S117962
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items